Alpha-Synuclein Biomarkers for Parkinson’s Disease and Lewy Body Dementia: From Brain Pathology to Blood Test

The diagnosis of Parkinson’s disease (PD) and Lewy body dementia (LBD) has long depended on clinical observation alone — an approach that is too often inaccurate and almost always too late. For decades, neurologists have had no reliable biological test to confirm that a living patient’s symptoms stem from the accumulation of misfolded alpha-synuclein protein in the brain. That is now changing rapidly.

Advances in biomarker science are delivering the tools clinicians have long needed: objective, biology-based tests that can detect synuclein pathology years before irreversible neurodegeneration takes hold. At the forefront of this revolution is a deceptively simple idea — that neurons continuously shed tiny membrane-bound vesicles called exosomes into the bloodstream, and that those vesicles carry a molecular fingerprint of what is happening inside the brain. Companies like NeuroDex are harnessing this biology to create blood tests for alpha-synuclein pathology that require nothing more than a routine venepuncture.

This article explains the science of alpha-synuclein, why it is the central biomarker target for Parkinson’s disease and Lewy body dementia, how neuron-derived exosomes (NDEs) enable blood-based detection, and what the NeuroDex ExoSORT™ platform means for patients, clinicians, and the future of neurological drug development.

What Is Alpha-Synuclein?

Alpha-synuclein (α-syn) is a 140-amino-acid protein encoded by the SNCA gene and expressed abundantly at the presynaptic terminals of neurons throughout the brain. Under normal conditions, it participates in regulating neurotransmitter release and synaptic vesicle recycling. In health, it exists primarily as a soluble monomer or as a membrane-associated helical form. In disease, however, it misfolds and self-assembles into toxic oligomers and insoluble amyloid fibrils.

These misfolded fibrils accumulate inside neurons as Lewy bodies and Lewy neurites — the neuropathological hallmarks shared by Parkinson’s disease, dementia with Lewy bodies (DLB), Parkinson’s disease dementia (PDD), and multiple system atrophy (MSA). Together these are called synucleinopathies. Critically, misfolded alpha-synuclein behaves in a prion-like fashion: pathological seeds can propagate from cell to cell and spread through neural networks, explaining the stereotyped pattern of disease progression described by Braak’s staging hypothesis.

Because alpha-synuclein aggregation precedes the loss of dopaminergic neurons and the onset of motor symptoms by potentially a decade or more, it represents the ideal early biomarker target. Detecting misfolded or aggregated alpha-synuclein in accessible biological fluids or tissues in living patients is therefore one of the highest priorities in clinical neuroscience.

The Diagnostic Gap in Parkinson’s Disease and Lewy Body Dementia

Parkinson’s disease affects an estimated 10 million people worldwide and is the fastest-growing neurological disorder in terms of prevalence. Lewy body dementia — which encompasses DLB and PDD — is the second most common form of degenerative dementia, yet it remains profoundly under-recognised. Postmortem studies consistently show that 20–30% of clinically diagnosed Parkinson’s disease cases are incorrect, while up to 50% of Lewy body dementia cases are misdiagnosed as Alzheimer’s disease during life.

The consequences of misdiagnosis are severe. Patients with Lewy body dementia have life-threatening sensitivity to antipsychotic medications, which may be prescribed inappropriately when a clinician suspects Alzheimer’s disease or a primary psychiatric disorder. Patients with Parkinson’s disease who are erroneously diagnosed with essential tremor or drug-induced parkinsonism may miss the opportunity to receive neuroprotective therapies once they become available. And misclassification of patients in clinical trials for disease-modifying drugs undermines the validity of efficacy data, contributing to the high failure rate of neurodegeneration trials.

The field has therefore converged on a clear imperative: develop a reliable, accessible, and scalable biological test for alpha-synuclein pathology that can be used not only in specialist neurology centres but across all clinical settings where these patients present.

The Blood-Based Biomarker Challenge: Why Plasma Alpha-Synuclein Alone Is Insufficient

Alpha-synuclein is expressed throughout the body, not only in the brain. It is found in high concentrations in red blood cells, platelets, and peripheral tissues. As a result, total plasma or serum alpha-synuclein levels reflect systemic protein abundance and do not reliably distinguish patients with Parkinson’s disease from healthy individuals. Early studies measuring bulk plasma alpha-synuclein were largely inconclusive, and the approach was widely considered insufficient for clinical use.

The solution to this problem lies not in measuring alpha-synuclein everywhere it appears in blood, but in measuring it specifically in the fraction derived from neurons in the central nervous system. This is where neuron-derived exosomes offer a transformative advantage.

Neuron-Derived Exosomes: A Liquid Biopsy of the Brain

Exosomes are small extracellular vesicles — typically 30–150 nanometres in diameter — that are produced by all cell types through the fusion of multivesicular endosomes with the plasma membrane. They are secreted continuously into the extracellular space and enter the systemic circulation, where they can be detected in blood plasma. Because exosomes carry molecular cargo — proteins, lipids, RNA, and DNA — that reflects the biology of the cell from which they originated, they function as circulating biological messengers.

Crucially, exosomes are small enough to cross the blood-brain barrier in both directions. Neurons in the central nervous system shed exosomes that traverse the blood-brain barrier and enter the peripheral circulation. These neuron-derived exosomes (NDEs) carry neuronal proteins including alpha-synuclein, tau, TDP-43, and neurofilament light chain — providing a “liquid biopsy” window into the biochemistry of brain cells without the need for invasive CSF collection.

The challenge is specificity: only a small proportion of exosomes in peripheral blood originate from neurons. The majority come from platelets, red blood cells, endothelial cells, and other peripheral tissues. Simply measuring alpha-synuclein in total plasma exosomes would reintroduce the signal dilution problem that plagues bulk plasma measurements. The key, therefore, is to selectively isolate only those exosomes that originated from neurons — and to do so with sufficient sensitivity and reproducibility for clinical application.

NeuroDex and the ExoSORT™ Platform: Engineering a Brain-Specific Blood Test

NeuroDex, Inc. — a Natick, Massachusetts-based diagnostics company — has developed a proprietary immunoaffinity isolation system called ExoSORT™ that selectively captures neuron-derived and oligodendrocyte-derived extracellular vesicles from blood plasma. The ExoSORT™ platform exploits neuronal and oligodendroglial surface markers to pull down cell-type-specific exosomes from the heterogeneous mixture of vesicles present in plasma, enabling downstream quantification of alpha-synuclein that is genuinely brain-derived.

Once NDEs are isolated, NeuroDex measures alpha-synuclein — both within the vesicles and on their surface — using high-sensitivity immunoassay techniques including electrochemiluminescence ELISA. The platform also supports seed amplification assay (RT-QuIC) on NDE-derived material, allowing detection of misfolded, aggregation-competent alpha-synuclein conformers that are the pathological species of interest in synucleinopathies, rather than simply total protein abundance.

Distinguishing Parkinson’s Disease from Multiple System Atrophy

One of the most important clinical applications of the NDE approach is the differential diagnosis of synucleinopathies. Parkinson’s disease and multiple system atrophy (MSA) are both alpha-synuclein diseases, but they differ fundamentally in the cell type most affected: in PD, alpha-synuclein aggregates predominantly in neurons, while in MSA it accumulates predominantly in oligodendrocytes. This biological distinction maps directly onto the NDE measurement strategy.

Published research using exosome immunoprecipitation with CNS cell markers has demonstrated that the ratio of alpha-synuclein in oligodendrocyte-derived versus neuron-derived exosomes is significantly elevated in MSA compared to PD. In two independent cohorts, a multinomial logistic model combining this ratio with total alpha-synuclein concentration separated PD from MSA with an AUC of 0.902, corresponding to approximately 90% sensitivity and 86% specificity. This is a remarkable performance for a blood-based test addressing a diagnostic distinction that currently requires specialist clinical assessment and is only confirmed definitively at autopsy.

Michael J. Fox Foundation and ADDF Validation Studies

The scientific merit and clinical potential of the NeuroDex approach has attracted investment from two of the most prestigious funders in neurodegeneration research. NeuroDex has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to conduct a study titled “Blood Test for Parkinson’s Stratification based on Neuron and Oligodendrocyte Derived Extracellular Vesicles,” expanding its investigation to large, well-established clinical cohorts totalling over 500 subjects.

NeuroDex has also received an award from the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator for clinical validation of a blood test using neuron-derived exosomes for the detection of alpha-synuclein and TDP-43 pathologies in patients with Alzheimer’s disease and related dementias. This work addresses the substantial proportion of dementia patients who carry mixed pathologies — postmortem studies indicate that over 85% of dementia cases present with more than one underlying neuropathological process — and who would benefit from precise subclassification to receive appropriate therapy.

GLP and CLIA Compliance: A Path to Clinical Translation

NeuroDex operates a CLIA-certified laboratory and conducts its biomarker work under Good Laboratory Practice (GLP) standards, positioning the ExoSORT™ platform for formal analytical and clinical validation. The company’s development roadmap progresses from discovery-phase studies through analytical validation in its CLIA lab, to large-scale clinical validation and ultimately commercialisation as both a diagnostic test and a clinical trial biomarker tool.

Alpha-Synuclein Biomarkers in Lewy Body Dementia: Filling the Diagnostic Void

Lewy body dementia presents diagnostic challenges that are in some respects even more acute than those in Parkinson’s disease. The clinical features of dementia with Lewy bodies — fluctuating cognition, recurrent visual hallucinations, REM sleep behaviour disorder, and parkinsonism — overlap substantially with Alzheimer’s disease. Current supportive biomarkers for DLB, including dopaminergic imaging (DaTscan) and cardiac MIBG scintigraphy, detect indirect consequences of Lewy body pathology rather than the pathological protein itself.

An alpha-synuclein-specific blood test based on NDEs directly detects the pathological protein responsible for Lewy body formation. This approach would enable definitive distinction of DLB from Alzheimer’s disease in living patients — a distinction with critical clinical implications given the antipsychotic sensitivity that makes DLB patients vulnerable to serious adverse drug reactions. It would also identify the substantial subset of patients with Alzheimer’s disease who carry co-existing Lewy body pathology, enabling precision medicine approaches informed by the patient’s actual underlying biology.

Broader Applications: Beyond Alpha-Synuclein

The NeuroDex NDE platform is not limited to alpha-synuclein. Because neuron-derived exosomes carry a broad cargo of neuronal proteins, the same ExoSORT™ isolation methodology can be applied to measure other clinically important biomarkers from a single blood draw. The NeuroDex panel currently includes tau and phosphorylated tau for Alzheimer’s disease monitoring, TDP-43 for ALS and frontotemporal dementia, neurofilament light chain (NF-L) for neuroinflammation and brain injury, and autophagy markers including LC3 and cathepsin D.

This multianalyte capability is particularly valuable for clinical trials and for the growing patient population with mixed neurodegenerative pathologies. A single, minimally invasive blood test that simultaneously characterises alpha-synuclein, tau, and TDP-43 burden would transform the feasibility of precision stratification in both clinical practice and drug development.

The Broader Biomarker Landscape: Complementary Approaches

NeuroDex’s blood-based NDE approach exists within a rapidly maturing alpha-synuclein biomarker ecosystem. Cerebrospinal fluid (CSF) seed amplification assays (SAA) — validated in the landmark 2023 PPMI study published in The Lancet Neurology — have demonstrated sensitivity of 87.7% and specificity of 96.3% for Parkinson’s disease. However, CSF collection requires lumbar puncture, limiting its utility for routine clinical use, repeat sampling, and large-scale population screening.

Skin biopsy detection of phosphorylated alpha-synuclein in cutaneous nerve fibers and olfactory mucosa sampling represent additional minimally invasive approaches that have shown high diagnostic accuracy. Each method has distinct advantages in terms of invasiveness, sensitivity, specificity, and scalability. The NDE blood test occupies a uniquely compelling position in this landscape: it combines the accessibility of a standard blood draw with the cell-type specificity needed to detect genuinely brain-derived alpha-synuclein signals, and it can potentially be deployed in any laboratory setting worldwide without specialist facilities.

Implications for Clinical Trials and Drug Development

The development of reliable alpha-synuclein biomarkers has profound implications for the pipeline of disease-modifying therapies targeting synucleinopathies. Anti-alpha-synuclein immunotherapies, aggregation inhibitors, and SNCA-targeting gene therapies are all in active clinical development — and all require validated biomarkers to enrich trial populations, confirm target engagement, and measure pharmacodynamic response.

A blood-based alpha-synuclein test that can be performed repeatedly without patient burden or specialist infrastructure would be transformative for trial feasibility. It would enable screening of large populations to identify synuclein-positive individuals, longitudinal monitoring of biomarker response to treatment, and stratification of patients by synucleinopathy subtype — all using a test that can be performed at a local clinic or even integrated into a routine annual health check.

The 2024 International Parkinson and Movement Disorder Society (MDS) biological staging framework, which formally requires biological evidence of alpha-synuclein pathology for a diagnosis of Parkinson’s disease, underscores the urgency of making validated alpha-synuclein tests available at scale. Blood-based NDE platforms are uniquely positioned to meet this need.

Conclusion

Alpha-synuclein is the defining biomarker of Parkinson’s disease and Lewy body dementia, and the field is rapidly closing the gap between the science of synuclein pathology and practical clinical diagnostics. The insight that neuron-derived exosomes in peripheral blood carry brain-specific alpha-synuclein — and that cell-type-selective isolation can resolve the signal from the noise of systemic protein expression — represents a conceptual and technical breakthrough.

NeuroDex’s ExoSORT™ platform embodies this breakthrough in a clinically actionable form: a minimally invasive blood test that provides a liquid biopsy of the brain, with the sensitivity and specificity to distinguish synucleinopathy subtypes, the analytical rigour of GLP and CLIA compliance, and the scalability to support both routine diagnostics and large-scale clinical trials. Backed by grants from the Michael J. Fox Foundation and the Alzheimer’s Drug Discovery Foundation, and grounded in peer-reviewed science demonstrating high diagnostic performance, NeuroDex represents a significant step toward the day when a blood test for Parkinson’s disease is as routine as a cholesterol panel.

For patients, this means earlier and more accurate diagnoses. For clinicians, it means confident differential diagnosis without invasive procedures. And for the neurodegeneration field as a whole, it means the tools needed to finally test — and prove — that disease-modifying therapies can change the course of Parkinson’s disease and Lewy body dementia.

References

1. Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839–840. doi:10.1038/42166
2. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211. doi:10.1016/S0197-4580(02)00065-9
3. Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol. 2021;20(5):385–397. doi:10.1016/S1474-4422(21)00030-2
4. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100. doi:10.1212/WNL.0000000000004058
5. Siderowf A, Concha-Marambio L, Lafontant D-E, et al. Assessment of heterogeneity among participants in the PPMI cohort using alpha-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 2023;22(5):407–417. doi:10.1016/S1474-4422(23)00109-6
6. Parnetti L, Gaetani L, Eusebi P, et al. CSF and blood biomarkers for Parkinson’s disease. Lancet Neurol. 2019;18(6):573–586. doi:10.1016/S1474-4422(19)30024-9
7. Thery C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018). J Extracell Vesicles. 2018;7(1):1535750. doi:10.1080/20013078.2018.1535750
8. Goetzl EJ, Boxer A, Schwartz JB, et al. Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. Neurology. 2015;85(1):40–47. doi:10.1212/WNL.0000000000001702
9. Jiang C, Hopfner F, Berg D, et al. α-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson’s disease from multiple system atrophy. Acta Neuropathol. 2021;142(3):495–512. doi:10.1007/s00401-021-02324-0
10. Kluge A, Bunk J, Schaeffer E, et al. Detection of neuron-derived pathological α-synuclein in blood. Brain. 2022;145(9):3045–3058. doi:10.1093/brain/awac161
11. Bellomo G, Paolini Paoletti F, De Luca CMG, et al. Neuronally derived extracellular vesicle α-synuclein as a serum biomarker for individuals at risk of developing Parkinson disease. JAMA Neurol. 2024;81(1):96–104. doi:10.1001/jamaneurol.2023.4398
12. NeuroDex, Inc. Advanced Neurodiagnostic Platform. NeuroDex, 2025. Available at: https://neurodex.co/neurodiagnostic-platform/
13. The Michael J. Fox Foundation for Parkinson’s Research. Blood Test for Stratifying People with Parkinson’s Disease based on Extracellular Vesicles Derived from Neurons. MJFF Grant Portfolio. Available at: https://www.michaeljfox.org/grant/blood-test-stratifying-people-parkinsons-disease-based-extracellular-vesicles-derived-neurons
14. Alzheimer’s Drug Discovery Foundation. NeuroDex – Diagnostics Accelerator Portfolio. ADDF, 2023. Available at: https://www.alzdiscovery.org/research-and-grants/portfolio-details/21925702
15. NeuroDex, Inc. NeuroDex Announces Award from Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator. Press Release, March 2023. Available at: https://neurodex.co/neurodex-award-addf/
16. Simuni T, Chahine LM, Poston K, et al. A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024;23(2):178–190. doi:10.1016/S1474-4422(23)00405-2
17. Outeiro TF, Koss DJ, Erskine D, et al. Dementia with Lewy bodies: an update and outlook. Mol Neurodegener. 2019;14(1):5. doi:10.1186/s13024-019-0306-8
18. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–1601. doi:10.1002/mds.26424